# Phase II Trial of Erlotinib in Advanced Pancreatic Cancer

> **NCT00497224** · PHASE2 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 51 (actual)

## Conditions studied

- Cancer
- Pancreas

## Interventions

- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00497224
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-12
- **Final completion:** 2013-06
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2019-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00497224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00497224, "Phase II Trial of Erlotinib in Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00497224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*